Yaz and Yasmin Safety and Labeling
Author:Law Office of Rudolph F.X. Migliore, P.C.
On December 8, 2011, Food and Drug Administration panelists voted 21-5 that Bayer’s current labeling on Yaz and Yasmin, (drospirenoen containing drugs,) is “inadequate” and “needs more information” regarding the potential risk of blood clots in the legs and lungs.
The panelists discussed conflicting data for over 9 hours regarding blood clot risk of Yaz, compared to other medications. The overwhelming majority of panelists said that because of the potentially ..read more
